Lennartz, David Paul
Seikrit, Claudia
Wied, Stephanie
Fitzner, Christina
Eitner, Frank
Hilgers, Ralf-Dieter
Rauen, Thomas
Floege, Jürgen
Funding for this research was provided by:
RWTH Aachen
Article History
Received: 6 May 2020
Accepted: 11 August 2020
First Online: 27 August 2020
Compliance with ethical standards
:
: J.F. has received consultant honoraria from Omeros, USA, Retrophin, USA and Calliditas, Sweden. The other authors declare no competing financial interests.
: The STOP-IgAN trial was performed in line with with the principles of the 1964 Declaration of Helsinki and approval was granted by the Ethics Committees at each participating center (ExternalRef removed, NCT00554502).
: The STOP-IgAN trial was conducted as a multicenter, open label, randomized, controlled study between February 2008 and October 2011 (ExternalRef removed, NCT00554502). All data presented in this secondary analysis were recorded as detailed in the study protocol [CitationRef removed]. The STOP-IgAN trial was performed in line with the principles of the 1964 Declaration of Helsinki and approval was granted by the Ethics Committees at each participating center.
: Written informed consent was obtained from all individual participants included in the STOP-IgAN trial prior to trial enrollment. This consent included collection of serum samples.